EP3999075A1 - Sequences siarn ciblant l'expression des genes jak1 ou jak3 humains pour une utilisation therapeutique - Google Patents
Sequences siarn ciblant l'expression des genes jak1 ou jak3 humains pour une utilisation therapeutiqueInfo
- Publication number
- EP3999075A1 EP3999075A1 EP20740302.3A EP20740302A EP3999075A1 EP 3999075 A1 EP3999075 A1 EP 3999075A1 EP 20740302 A EP20740302 A EP 20740302A EP 3999075 A1 EP3999075 A1 EP 3999075A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- nucleotide sequence
- sequence seq
- strand comprises
- dsrna
- antisense strand
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000014509 gene expression Effects 0.000 title claims description 48
- 241000282414 Homo sapiens Species 0.000 title claims description 24
- 108020004459 Small interfering RNA Proteins 0.000 title description 66
- 230000008685 targeting Effects 0.000 title description 12
- 230000001225 therapeutic effect Effects 0.000 title description 8
- 101150079478 jak1 gene Proteins 0.000 title 1
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 119
- 239000002773 nucleotide Substances 0.000 claims abstract description 117
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims abstract description 100
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims abstract description 100
- 230000000692 anti-sense effect Effects 0.000 claims abstract description 64
- 108091081021 Sense strand Proteins 0.000 claims abstract description 58
- 229920002477 rna polymer Polymers 0.000 claims abstract description 24
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 8
- 108010000837 Janus Kinase 1 Proteins 0.000 claims description 52
- 108010019421 Janus Kinase 3 Proteins 0.000 claims description 51
- 238000000034 method Methods 0.000 claims description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 108020004999 messenger RNA Proteins 0.000 claims description 12
- 230000019491 signal transduction Effects 0.000 claims description 12
- 230000004064 dysfunction Effects 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 9
- 101150069380 JAK3 gene Proteins 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 238000000338 in vitro Methods 0.000 claims description 6
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 230000001404 mediated effect Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 claims 8
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 56
- 102000002295 Janus Kinase 1 Human genes 0.000 description 43
- 108090000623 proteins and genes Proteins 0.000 description 41
- 102000006500 Janus Kinase 3 Human genes 0.000 description 38
- 102000015617 Janus Kinases Human genes 0.000 description 37
- 108010024121 Janus Kinases Proteins 0.000 description 37
- 239000003112 inhibitor Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 12
- 230000036961 partial effect Effects 0.000 description 12
- 238000001890 transfection Methods 0.000 description 12
- 239000012098 Lipofectamine RNAiMAX Substances 0.000 description 11
- 102220497176 Small vasohibin-binding protein_T47D_mutation Human genes 0.000 description 9
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 102000049918 human JAK1 Human genes 0.000 description 7
- 102100033444 Tyrosine-protein kinase JAK2 Human genes 0.000 description 6
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical group NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 6
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical group O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 6
- 238000000126 in silico method Methods 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 101150112014 Gapdh gene Proteins 0.000 description 5
- 241001529936 Murinae Species 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 102000049912 human JAK3 Human genes 0.000 description 4
- 238000012405 in silico analysis Methods 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 238000011002 quantification Methods 0.000 description 4
- 239000013598 vector Substances 0.000 description 4
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 101100371344 Homo sapiens TYK2 gene Proteins 0.000 description 3
- 101000997832 Homo sapiens Tyrosine-protein kinase JAK2 Proteins 0.000 description 3
- 101150009057 JAK2 gene Proteins 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 101710140204 Signal transducer and transcription activator Proteins 0.000 description 3
- 101150033562 TYK2 gene Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 229940104302 cytosine Drugs 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000003531 protein hydrolysate Substances 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 241000701161 unidentified adenovirus Species 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 102100032126 Aminopeptidase B Human genes 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000775829 Homo sapiens Aminopeptidase B Proteins 0.000 description 2
- 101000802365 Homo sapiens Zinc finger SWIM domain-containing protein 4 Proteins 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 108091028664 Ribonucleotide Proteins 0.000 description 2
- 108091027967 Small hairpin RNA Proteins 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 206010052779 Transplant rejections Diseases 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 102100034991 Zinc finger SWIM domain-containing protein 4 Human genes 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002679 microRNA Substances 0.000 description 2
- 206010028537 myelofibrosis Diseases 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000002336 ribonucleotide Substances 0.000 description 2
- 125000002652 ribonucleotide group Chemical group 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000004055 small Interfering RNA Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102100027769 2'-5'-oligoadenylate synthase 1 Human genes 0.000 description 1
- 102100040071 ARL14 effector protein Human genes 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical group NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 102100032583 Calcium-dependent secretion activator 2 Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 102100027723 Endogenous retrovirus group K member 6 Rec protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102100030771 Ferrochelatase, mitochondrial Human genes 0.000 description 1
- 101001008907 Homo sapiens 2'-5'-oligoadenylate synthase 1 Proteins 0.000 description 1
- 101000890563 Homo sapiens ARL14 effector protein Proteins 0.000 description 1
- 101000783802 Homo sapiens Actin-binding LIM protein 1 Proteins 0.000 description 1
- 101000867778 Homo sapiens Calcium-dependent secretion activator 2 Proteins 0.000 description 1
- 101000843611 Homo sapiens Ferrochelatase, mitochondrial Proteins 0.000 description 1
- 101001046976 Homo sapiens KN motif and ankyrin repeat domain-containing protein 3 Proteins 0.000 description 1
- 101100021863 Homo sapiens LRCH2 gene Proteins 0.000 description 1
- 101000941888 Homo sapiens Leucine-rich repeat and calponin homology domain-containing protein 2 Proteins 0.000 description 1
- 101000844245 Homo sapiens Non-receptor tyrosine-protein kinase TYK2 Proteins 0.000 description 1
- 101000579354 Homo sapiens PHD finger protein 21A Proteins 0.000 description 1
- 101000608154 Homo sapiens Peroxiredoxin-like 2A Proteins 0.000 description 1
- 101001117219 Homo sapiens Polymerase delta-interacting protein 3 Proteins 0.000 description 1
- 101000652707 Homo sapiens Transcription initiation factor TFIID subunit 4 Proteins 0.000 description 1
- 101000838103 Homo sapiens Transmembrane protein 120B Proteins 0.000 description 1
- 101000785728 Homo sapiens Zinc finger FYVE domain-containing protein 1 Proteins 0.000 description 1
- 101000915604 Homo sapiens Zinc finger protein 782 Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 1
- 101150035169 K3 gene Proteins 0.000 description 1
- 102100022889 KN motif and ankyrin repeat domain-containing protein 3 Human genes 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 102100032692 Leucine-rich repeat and calponin homology domain-containing protein 2 Human genes 0.000 description 1
- 208000005777 Lupus Nephritis Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108700011259 MicroRNAs Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102100032028 Non-receptor tyrosine-protein kinase TYK2 Human genes 0.000 description 1
- 102100028222 PHD finger protein 21A Human genes 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102100036619 Palmitoyltransferase ZDHHC23 Human genes 0.000 description 1
- 102100039896 Peroxiredoxin-like 2A Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000017143 RNA Polymerase I Human genes 0.000 description 1
- 108010013845 RNA Polymerase I Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 102000014450 RNA Polymerase III Human genes 0.000 description 1
- 108010078067 RNA Polymerase III Proteins 0.000 description 1
- 102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 1
- 108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108050007918 Transcription factor STAT Proteins 0.000 description 1
- 102000000887 Transcription factor STAT Human genes 0.000 description 1
- 102100030833 Transcription initiation factor TFIID subunit 4 Human genes 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102100028599 Transmembrane protein 120B Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 102100026420 Zinc finger FYVE domain-containing protein 1 Human genes 0.000 description 1
- 102100028584 Zinc finger protein 782 Human genes 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 238000001151 non-parametric statistical test Methods 0.000 description 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000009437 off-target effect Effects 0.000 description 1
- 229950005564 patisiran Drugs 0.000 description 1
- 230000008823 permeabilization Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/10—Protein-tyrosine kinases (2.7.10)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Definitions
- the sense strand consists of the nucleotide sequence SEQ ID NO: 5 and the antisense strand consists of the nucleotide sequence SEQ ID NO: 6; or
- the sense strand consists of the nucleotide sequence SEQ ID NO: 7 and the antisense strand consists of the nucleotide sequence SEQ ID NO: 8;
- the DNA plasmids for the expression of dsRNA are typically introduced into the target cells by transfection according to the techniques and with the aid of vehicles well known to those skilled in the art.
- the efficiency of transfection can be monitored, for example, by using a fluorescent label such as GFP as a reporter gene.
- step (a) at. the introduction into said cell of the dsRNA according to the invention; and B. maintaining the cell produced in step (a) for a time sufficient to cause degradation of the mRNA of a JAK1 or JAK3 gene, thereby inhibiting the expression of JAK1 or JAK3 in the cell.
- PC3 cells overexpressing JAK3-GFP were finally transfected with different concentrations of siRNA (from 0.5 pM to 12.5 pM) using Lipofectamine RNAimax for 48 h. cells were lysed using standard lysis buffer. The protein lysates were then analyzed by Western blotting for the expression of JAK3 or JAK1 and GAPDH.
- Figure 8 shows the results of a Western blot experiment representative of 3 independent experiments.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP23197707.5A EP4282481A3 (fr) | 2019-07-15 | 2020-07-13 | Sequences siarn ciblant l'expression des genes jak1 ou jak3 humains pour une utilisation therapeutique |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1907968A FR3098712A1 (fr) | 2019-07-15 | 2019-07-15 | Séquences siARN ciblant l'expression des gènes JAK1 ou JAK3 humains pour une utilisation thérapeutique |
PCT/EP2020/069768 WO2021009126A1 (fr) | 2019-07-15 | 2020-07-13 | Sequences siarn ciblant l'expression des genes jak1 ou jak3 humains pour une utilisation therapeutique |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23197707.5A Division EP4282481A3 (fr) | 2019-07-15 | 2020-07-13 | Sequences siarn ciblant l'expression des genes jak1 ou jak3 humains pour une utilisation therapeutique |
Publications (1)
Publication Number | Publication Date |
---|---|
EP3999075A1 true EP3999075A1 (fr) | 2022-05-25 |
Family
ID=68806914
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP20740302.3A Withdrawn EP3999075A1 (fr) | 2019-07-15 | 2020-07-13 | Sequences siarn ciblant l'expression des genes jak1 ou jak3 humains pour une utilisation therapeutique |
EP23197707.5A Pending EP4282481A3 (fr) | 2019-07-15 | 2020-07-13 | Sequences siarn ciblant l'expression des genes jak1 ou jak3 humains pour une utilisation therapeutique |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP23197707.5A Pending EP4282481A3 (fr) | 2019-07-15 | 2020-07-13 | Sequences siarn ciblant l'expression des genes jak1 ou jak3 humains pour une utilisation therapeutique |
Country Status (5)
Country | Link |
---|---|
US (1) | US20220298512A1 (fr) |
EP (2) | EP3999075A1 (fr) |
JP (1) | JP2022541212A (fr) |
FR (1) | FR3098712A1 (fr) |
WO (1) | WO2021009126A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113667733B (zh) * | 2021-07-12 | 2023-08-01 | 华中科技大学同济医学院附属协和医院 | circRNA PRDM5在钙化性主动脉瓣疾病的诊断试剂盒及治疗药物开发中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5705625A (en) * | 1994-12-15 | 1998-01-06 | The Johns Hopkins University School Of Medicine | Nucleic Acid Encoding novel protein tyrosine kinase |
FR2929292A1 (fr) * | 2008-03-28 | 2009-10-02 | Exonhit Therapeutics S A Sa | Procede et methodes de diagnostic de la maladie d'alzheimer |
-
2019
- 2019-07-15 FR FR1907968A patent/FR3098712A1/fr active Pending
-
2020
- 2020-07-13 EP EP20740302.3A patent/EP3999075A1/fr not_active Withdrawn
- 2020-07-13 US US17/627,606 patent/US20220298512A1/en active Pending
- 2020-07-13 JP JP2022502515A patent/JP2022541212A/ja active Pending
- 2020-07-13 EP EP23197707.5A patent/EP4282481A3/fr active Pending
- 2020-07-13 WO PCT/EP2020/069768 patent/WO2021009126A1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
EP4282481A2 (fr) | 2023-11-29 |
EP4282481A3 (fr) | 2024-02-28 |
FR3098712A1 (fr) | 2021-01-22 |
WO2021009126A1 (fr) | 2021-01-21 |
US20220298512A1 (en) | 2022-09-22 |
JP2022541212A (ja) | 2022-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6236498B2 (ja) | 非対称性干渉rnaの組成物およびその使用 | |
RU2744194C2 (ru) | Иммунотерапия рака | |
US9953131B2 (en) | Multi-targeting short interfering RNAs | |
KR101852210B1 (ko) | 진피 및 섬유증성 적응증에서의 rna 간섭 | |
JP2014097072A5 (fr) | ||
Martínez et al. | Short-interference RNAs: becoming medicines | |
WO2021009126A1 (fr) | Sequences siarn ciblant l'expression des genes jak1 ou jak3 humains pour une utilisation therapeutique | |
WO2007149521A2 (fr) | Motifs nucléotidiques produisant des éléments de localisation et procédés d'utilisation | |
EP1651762B1 (fr) | PETITS ARN INTERFERENTS SPECIFIQUES DES SOUS-UNITES ALPHA, ALPHA' ET ß DE LA PROTEINE KINASE CK2 ET LEURS APPLICATIONS | |
CN110996969B (zh) | 纤维化疾病治疗剂 | |
KR102321426B1 (ko) | 남성형 탈모 표적 유전자의 발현을 억제하는 비대칭 siRNA | |
JP7241098B2 (ja) | 線維症治療剤 | |
Schmitz et al. | Effect of small interfering RNA 3'-end overhangs on chemosensitivity to thymidylate synthase inhibitors | |
US20060241069A1 (en) | Treatment of hyperproliferative disease | |
JP2006500017A (ja) | RNA発現のためのアデノウイルスのVA1PolIII発現システム | |
CN114144526B (zh) | Eph2a适配体及其用途 | |
EP4124656A1 (fr) | Micro arn pd-l1 | |
JP2019517819A (ja) | 抗癌治療の介入 | |
JP5632101B2 (ja) | microRNAを有効成分とするIMPDH阻害剤 | |
KR20100051614A (ko) | 암치료를 위한 rnaⅰ 매개된 numa의 녹다운 | |
Jian et al. | RNA therapy: Are we using the right molecules? | |
Wheeler et al. | RNAi as a potential new therapy for HIV infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: UNKNOWN |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20220113 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20230110 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20230626 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20231107 |